North-American benchmark WTI is showing signs of extreme sentiment, which suggests that there might be reversal ahead.
Kindly note that extreme sentiment doesn't necessarily result in immediate reversal, as a matter of fact irrational exuberance (a term coined by Nobel Laureate Robert Schiller) can continue for greater extent. However, it surely indicates that it might be time to stay alert and cautious.
Last week, WTI not only reached lowest level since 2008/09 crisis when price traded as low as low as $36/barrel, it completed its longest weekly directional move in more than three decades at least.
WTI has declined for ninth straight week and on its way to mark 10 this week.
This extreme one sided move suggests that there might be reversal ahead. However since fundamental theme, which is supply glut, is in line with this move, sentiment extreme might continue further.
It is advised to stay cautious and look for early signs of reversal candles in both daily and weekly chart. Friday WTI almost formed but finally failed to build a very bullish hammer or Dragonfly Doji. Nevertheless, It has formed a medium bullish Doji with $39.5/barrel as leg low.
It is advised to stay cautious for further stronger signal.
WTI is currently trading at $42/barrel.


NHS shakeup: if it sounds like we’ve been here before, it’s because we have
Global Bond Selloff Pressures Stocks as Rising Oil Prices Fuel Inflation Fears
Macquarie Names Five Taiwan AI Stocks Set to Benefit From Data Center Growth in 2026
Gold Cracks Below $4,500 as Safe-Haven Shine Fades; Technical Breakdown Signals Sell-on-Rallies Toward $4,000
Cuba needs a long-term solution to its energy crisis
Gold Cracks Below $4,500 as Safe-Haven Shine Fades; Technical Breakdown Signals Sell-on-Rallies Toward $4,000
Spying, Southampton and economic pressure cooker of the ‘richest match in football’
Goldman Sachs Sees Stronger U.S. Dollar as Global Economic Gaps Widen
AI-Driven Memory Chip Prices May Be Skewing U.S. Inflation Data, Fed Minutes Suggest
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks 



